Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.
Thomas W. Dubensky, PhD
Advertisement
Articles by Thomas W. Dubensky, PhD
Advertisement
Latest Updated Articles
Thomas Dubensky on How ADU-S100 Activates STINGPublished: April 29th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5